Acuamark Diagnostics

The page states that cancer is usually asymptomatic in its early stages and that early detection is challenging. It asks whether a blood sample can detect early signs.

The page features the latest articles and news about the developing technology.

Last month, iCareDx announced that it was rebranding itself as Acuamark Diagnostics as it works to raise funds for its first round of clinical testing.

iCareDx, Inc., a biotechnology company focused on blood-based early detection of cancer, today announced that it has changed its name to Acuamark Diagnostics,

AcuamarkDx announced that it has completed private placement of its Preferred Series AA3 stock in a round that was substantially oversubscribed.

With the election of the 2016 class, there are now 757 NAI Fellows, representing 229 research universities and governmental and non-profit research institutes.

The company aims to provide diagnostic detection tools for disease detection and monitoring.

The AcuamarkDx Code of Conduct guides the preservation of Acuamark Diagnostics’ mission, values, and vision. It helps the team make choices and outlines expectations for employees around the globe.

The company says inclusion, equity, and diversity are central to its mission and community impact. It celebrates differences and says diversity can help advance the global fight against cancer.

Acuamark Diagnostics has an experienced multidisciplinary team, which includes, highly distinguished diagnostic assay developers and a world-renowned scientific team of inventors of detection assays, multiplexing and sequencing technology.

The company says it will contact people who submit the form as soon as possible.

Acuamark Diagnostics develops technology which allows for highly accurate screening of blood to detect cancer markers at the early cancer stages.